Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

biOasis Enters into a License Agreement with MedImmune

Published: Saturday, March 22, 2014
Last Updated: Saturday, March 22, 2014
Bookmark and Share
Agreement for second generation versions of biOasis's Transcend.

biOasis Technologies Inc. has signed an evaluation agreement with MedImmune, the global biologics research and development arm of AstraZeneca.

Under the terms of the agreement, MedImmune will evaluate the therapeutic effect of its pre- clinical assets with next-generation versions of biOasis’s Transcend brain delivery platform.

Efficient transport of drugs targeted at the central nervous system is significantly hampered by the blood-brain barrier; biOasis’s Transcend platform, with its ability to shuttle compounds across this barrier, may hold a solution to this problem.

“Our working relationship with MedImmune began in November 2012. In our collaboration, we demonstrated transport of MedImmune’s antibodies into the brain using our first-generation Transcend vector,” said Dr. Reinhard Gabathuler, Chief Scientist at biOasis. “In addition, we introduced our second-generation Transcend vector into this collaboration and other programs we have underway, where we have observed equivalent or increased antibody transport into the brain. We feel that this next generation of Transcend will have specific advantages in transporting certain biologics into the brain.”

“MedImmune is pleased to be entering into this new agreement with biOasis,” said Dr. Carl Webster, Associate Director, Antibody Discovery and Protein Engineering, MedImmune. “Our recently completed initial collaboration was very positive and led us to decide to undertake this second project to investigate the therapeutic effect and utility of biOasis’s technology.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
3 Ways Viruses Have Changed Science for the Better
Viruses are really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
Mixed Up Cell Transportation Key Piece of ALS and Dementia Puzzle
Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Four Gut Bacteria Decrease Asthma Risk in Infants
New research by scientists at UBC and BC Children’s Hospital finds that infants can be protected from getting asthma if they acquire four types of gut bacteria by three months of age.
Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos